Clay B. Siegall, Ph.D., began his career in researching cures for cancer at the National Cancer Institute in 1988. In 1991 he performed research and development at the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Siegall went on to co-found Seattle Genetics, Inc. in 1998 and serves as the Chairman of the Board, President, and Chief Executive Officer. Seattle Genetics is a biotechnology company that specializes in developing drugs for the treatment of cancer. In particular at Seattle Genetics they focus on developing antibody-drug conjugates.
In 2011 the company had its cancer drug ADECTRIS approved by the FDA. This drug, which is also called brentuximab vedotin, treats two forms of lymphoma, classical Hodgkin Lymphoma and anaplastic large cell lymphoma. ADECTRIS is developed in a joint agreement between Seattle Genetics and Takeda Oncology where Seattle Genetics markets and provides the drug in the United States and Canada while Takeda Oncology is the provider for the rest of the world.
Dr. Clay Siegall plays a number of roles in the cancer research community. He serves on the board of directors for a number of pharmaceutical companies including Alder BioPharmaceuticals, Ultragenyx, and the Washington Roundtable. He also earned a number of rewards in the industry including being named as Entrepreneur of the Year in 2012 by Pacific Northwest Ernst & Young. In 2013 the was named by the University of Maryland as their Alumnus of the Year for Computer, Math, and Natural Sciences.
As the leader of Seattle Genetics, Dr. Seigall sets the overall strategy of the company and its culture. He is also responsible for forming strategic licenses with other biotechnology companies. Among the companies he has formed alliances with are AbbVie, Genentech, Pfizer, and GlaxoSmithKline. He also oversees the clinical research that the company performs as they have 9 cancer drugs under various stages of development.
Dr. Seigall graduate from the University of Maryland with a Bachelor’s Degree in Zoology. It was at George Washington University that he earned his Ph.D. in Genetics.